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Objective To study the release of free endotoxin from Escherichia coli exposed to varying concentrations of the
penicillin-binding protein (PBP) 3-specific b-lactam antibiotic cefuroxime, the aminoglycoside tobramycin,
and a combination of the two, and to test the relationship between bacterial killing rate and endotoxin release.
Methods A clinical isolate of Escherichia coli in logarithmic phase was exposed to 0.1, 2, 10, and 50  minimum
inhibitory concentration (MIC) of cefuroxime, tobramycin, and a combination of the two. Samples for viable
counts and endotoxin analysis were drawn immediately before and after the addition of the antibiotics and at
1, 2, 4, 6, and 24 h. All experiments were performed in triplicate. For the analysis of endotoxin, a chromogenic
limulus amoebocyte lysate assay was used.
Results Endotoxin liberation was found to be proportional to the number of killed bacteria for each antibiotic
regimen at each concentration level justifying the endotoxin-liberating potential to be expressed as release of
endotoxin per killed bacterium, an expression that was independent of the inoculum size. At all concentration
levels there was a statistically significant difference between the treatments, with the highest release of endotoxin
per killed bacterium for cefuroxime, lower for tobramycin and the lowest for the combination of the two
drugs (P  0.001). With increasing doses, there was a significant reduction (P  0.001) in the propensity to
release endotoxin. When the bacterial killing rate was correlated to the propensity to release endotoxin in
bacteria exposed to tobramycin or the combination of tobramycin and cefuroxime, a significant negative
correlation was found (P  0.01). This reduction in endotoxin release was not caused by an unspecific
endotoxin binding of tobramycin.
Conclusions Addition of tobramycin reduced the cefuroxime-induced endotoxin release per killed bacterium
to a level which was even lower than that of tobramycin alone in spite of an increased killing rate. Increasing
concentrations of tobramycin led to reduction in endotoxin release, which may be of benefit when dosing
aminoglycosides once daily.
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INTRODUCTION
Severe Gram-negative bacterial infections associated with shock
still have a significant mortality rate ranging from 30% up to
more than 80%, in spite of appropriate antibiotic treatment and
optimal intensive care [1–3]. An exaggerated systemic inflam-
matory response has been shown to mediate the initial patho-
physiologic changes which lead to severe sepsis and septic shock
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[4,5]. Since bacteria produce a range of extracellular products
and cell-wall constituents, such as endotoxin, all of which may
stimulate the systemic inflammatory response, considerable
interest has been focused on the release of these products,
especially on endotoxin [6–11].
A number of in-vitro experiments and in-vivo studies have
shown release of endotoxin when Gram-negative bacteria are
exposed to b-lactam antibiotics and other classes of anti-
microbial drugs [6–8,12–14]. After exposure to different b-
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lactam antibiotics, varying amounts of endotoxin are released
due to binding to different penicillin-binding proteins (PBP).
Thus, it has been shown that PBP 3-specific b-lactam
antibiotics, such as cefuroxime and aztreonam, release larger
quantities of free endotoxin than a PBP 2-specific b-lactam
antibiotic like imipenem [12,15]. In a limited number of inves-
tigations, aminoglycosides have also been studied [12,14,16,17].
Taken together, the results of these studies demonstrate a tend-
ency to lower release of endotoxin after exposure to an ami-
noglycoside compared with that after exposure to b-lactam
antibiotics. Since aminoglycosides have been shown to bind
directly to endotoxin [18,19], it has been speculated that ami-
noglycosides might neutralize endotoxin in a similar manner to
that shown for polymyxin B [20,21].
Due to these results, and the fact that an aminoglycoside in
combination with a cephalosporin is an often recommended
treatment for severe sepsis and septic shock [22], it was of
interest to further investigate the liberation of endotoxin from
bacteria after exposure to this combination. Furthermore, as it
has recently been proposed that the administration of amino-
glycosides once daily could be an advantage [23,24], it was of
special interest to investigate whether the more rapid killing
seen at higher doses of aminoglycosides was associated with an
increase in endotoxin release, or if this was counteracted by a
neutralization effect.
The specific aims of the present study were to study (1): the
release of free endotoxin from Escherichia coli exposed to varying
concentrations of the PBP 3-specific cefuroxime and the
aminoglycoside tobramycin (2); whether cefuroxime-induced
endotoxin release could be reduced by concomitant addition of
tobramycin at each concentration level; and (3) the relationship
between bacterial killing rate and endotoxin release in bacteria
exposed to varying concentrations of tobramycin and the com-
bination of tobramycin and cefuroxime.
In order to be able to compare endotoxin release with the
killing rate, which in this study is expressed as the time for a
2 log10 reduction of the colony forming units (CFU), it is of
importance to have a value indicating the propensity to release
endotoxin that is independent of the inoculum size. Therefore
in the present study, an additional investigation was also carried
out to determine whether the release of endotoxin for each
antibiotic regimen at each concentration level studied was pro-
portional to the reduction in CFU, which approximates to
the number of killed bacteria. If so, the endotoxin-liberating
propensity could be expressed as an amount of endotoxin which
is released per killed bacterium.
MATERIALS AND METHODS
Cultures
The bacterial strain used in this study was Escherichia coli (B 049–
3036), isolated at the Department of Clinical Microbiology,
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Uppsala, Sweden, from a patient with septicemia. Brain-heart
infusion (BHI) made with pyrogen-free water was used as
medium. Prior to each experiment, the test strain was inocu-
lated in a pyrogen-free glass tube containing BHI and incubated
for 6 h at 35 °C, resulting in a logarithmic-phase culture of
approximately 108–109 CFU/mL.
Antibiotics
The antibiotics were obtained as reference powders with
known potencies. Cefuroxime was obtained from Glaxo Well-
come AB, Gothenburg, Sweden and tobramycin from Eli Lilly
Sweden AB, Stockholm, Sweden.
Determination of minimum inhibitory concentrations
The minimum inhibitory concentrations (MICs) were deter-
mined in triplicate by two-fold macrodilution in broth with an
inoculum of approximately 105 CFU of the test strain per ml
according to NCCLs standard.
Determination of bacterial killing by viable counts
After incubation, the test strain in exponential growth-phase
was diluted tenfold in pyrogen-free water and thereafter 0.1 mL
of this aliquot was transferred to pyrogen-free glass vials con-
taining 10 mL of BHI to obtain a starting inoculum of approxi-
mately 105–106 CFU/mL. The strain was then exposed to
0.1, 2, 10, and 50  MIC of cefuroxime, tobramycin, and a
combination of cefuroxime and tobramycin, respectively, and
further incubated at 35 °C. One glass vial without antibiotics
served as a control. Samples for viable counts were drawn and
diluted in phosphate-buffered saline immediately before and
after addition of the antibiotics and at 1, 2, 4, 6, and 24 h. Three
dilutions of each sample were seeded on blood-agar plates
and incubated at 35 °C. All experiments were performed in
triplicate.
Determination of endotoxin
Endotoxin-free glass tubes and vials, preheated at 180 °C for
4 h, were used for all endotoxin assays. Sterile pyrogen-free
plastic syringes and pipettes were utilized as well as non-
pyrogenic filters. Samples for endotoxin analysis were drawn
concomitantly to those for viable counts. The samples were
kept on ice, diluted in pyrogen-free water, filtered, and frozen
at 20 °C pending analysis. Analyses of endotoxin were per-
formed in duplicate with the chromogenic limulus amoebocyte
lysate (LAL) assay (Whittaker M.A. Bioproducts, Walkersville,
MD, USA) [25].
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Determination of possible mechanisms for a tobramycin-caused
reduction in cefuroxime-induced endotoxin release
In order to further investigate possible mechanisms by which
tobramycin might interact with cefuroxime-induced endotoxin
release, tobramycin at concentrations of 0 (control), 10, 50, and
100  MIC was added to BHI spiked with endotoxin from
E. coli O55:B5 (Endotoxin Standard, Chromogenix, Mo¨lndal,
Sweden) to calculated concentrations of 500 and 2000 EU/mL,
respectively. Samples for endotoxin analysis were taken
immediately before administration of tobramycin and after 0.5,
2, and 4 h of incubation at 35 °C.
In another experiment with a design similar to that in the
previous experiments, bacteria exposed to cefuroxime at a con-
centration of 10  MIC for 2 h were further exposed to tob-
ramycin at the concentrations of 0 (control), 10, 50, and
100  MIC. Samples for endotoxin analysis were taken
immediately before and after administration of tobramycin.
The reduction in cefuroxime-induced endotoxin release in
comparison with that in the control was analyzed after an
additional 2 h.
Samples for determination of endotoxin and viable counts
were handled in a manner similar to that used in previous
experiments. All experiments were performed in triplicate.
Calculations and statistical methods
Reduction in CFU at various time points was calculated by
subtraction of the remaining number of CFU from that at time
zero. The number of CFU at time zero was calculated as the
mean of the values obtained immediately prior to and after the
addition of antibiotics. In the further calculations, the reduction
in CFU was considered to be equivalent to the number of
killed bacteria.
The endotoxin release was calculated similarly by subtracting
the endotoxin value at time zero from that obtained at the
various time points.
Reduction in cefuroxime-induced endotoxin release was
calculated as the percentage reduction in the samples to which
tobramycin was supplied in comparison with the control to
which no tobramycin was added.
Bacterial killing rate was determined as the time needed for
the antibiotic to kill 2 log10 CFU.
In order to determine whether there was a linear relationship
between the number of killed bacteria and the release of endo-
toxin for each antibiotic at each dosage level, regression analysis
was employed with the number of killed bacteria as the inde-
pendent and the amount of endotoxin released as the dependent
variable. Pearson’s correlation coefficient was computed to test
relationships between the number of killed bacteria and increase
in endotoxin concentration and between endotoxin-liberating
capacity and bacterial killing rate.
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Since the design of the experiment is a repeated measure-
ment, analysis of variance with repeated measurements was used
to compare the propensities to release endotoxin [26].
The experimental factor was treated as a random factor
whereas antibiotics, concentration and time, 2 h and 4 h, were
treated as fixed factors. The assumption for this analysis is that
the variable within each cell is normally distributed and with
the same variance within each cell. Since there was an increasing
variance for higher values of the response variable, the logarithm
was used to adjust for this.
Due to multiple statistical analyses, only P-values 0.01
were considered significant. Results are shown as mean 2 SE.
RESULTS
Bacterial killing rate
The MICs were 8 mg/L and 0.25 mg/L for cefuroxime and
tobramycin, respectively.
Exposure to 0.1  MIC of any of the three regimens gave
no significant reduction in growth compared with that of the
control, and this concentration level was therefore excluded
from further analysis.
There was a significant difference between the antibiotic
regimens with an increased killing rate for tobramycin and
tobramycin + cefuroxime at 10  MIC and 50  MIC
(P  0.001). The mean time for 2 log10 CFU killing of cef-
uroxime + tobramycin was 2.7 2 0.2 h at 2  MIC,
1.3 2 0.2 h at 10  MIC and 0.6 2 0.1 h at 50  MIC. The
corresponding figures for tobramycin and cefuroxime were
3.5 2 0.4 h, 1.2 2 0.3 h, and 0.7 2 0.1 h and 2.8 2 0.5 h,
2.6 2 0.4 h, and 1.9 2 0.1 h, respectively. At higher con-
centrations the time for a 2 log10 CFU killing was significantly
shorter for all three regimens (P  0.001). The concentration-
dependency of the killing rate was greater for tobramycin and
tobramycin plus cefuroxime than for cefuroxime alone which
was confirmed by using interaction terms in the multivariate
analysis (P  0.01).
Endotoxin release in relation to the number of killed bacteria
Most of the endotoxin was liberated during the first 2 h for all
treatments. Some additional increase was seen at the lower
concentrations after 4 h (Table 1). At 6 h and 24 h, there was
no further increase.
The number of killed bacteria during the first 4 h in an
individual experiment ranged from 105.3 to 106.5 CFU/mL.
Regression analysis of the data from the individual experiments
showed a linear relationship between the release of endotoxin
and the number of killed bacteria for each antibiotic regimen
at each dosage level with r2-values ranging from 0.61 to 0.96
(Table 2). The lower limit of the 95% confidence interval of
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Table 1 Endotoxin release 2 h and 4 h after exposure to
cefuroxime, tobramycin, or cefuroxime + tobramycin at
the concentrations of 2  MIC, 10  MIC, and 50  MIC
Increase in endotoxin
concentration (mean 2 SE)
after 2 h after 4 h
Antibiotic treatment (EU/mL) (EU/mL)
Cefuroxime 2  MIC 3900 2 2300 5300 2 3000
10  MIC 3800 2 3200 5600 2 3300
50  MIC 2300 2 1400 2100 2 1500
Tobramycin 2  MIC 3700 2 2700 6100 2 5000
10  MIC 760 2 490 1400 2 900
50  MIC 680 2 580 810 2 480
Tobramycin + 2  MIC 530 2 60 690 2 110
cefuroxime 10  MIC 260 2 70 250 2 60
50  MIC 170 2 90 160 2 40
Table 2 The r2-values for the correlation between the amount
of endotoxin released and the number of killed bacteria
for the antibiotic regimens at different concentrations
Antibiotic Cefuroxime +
concentration Cefuroxime Tobramycin tobramycin
2  MIC 0.96 0.98 0.87
10  MIC 0.91 0.84 0.61
50  MIC 0.92 0.94 0.85
The r2 value for all experiments (n = 54) was 0.50.
the intercept of the regression lines was 98 EU/mL and the
upper 260 EU/mL, thus including the origin of coordinates.
Therefore, these results strongly indicate that the endotoxin
liberation is proportional to the number of killed bacteria for
each antibiotic regimen at each dosage level and, consequently,
that the prerequisite for expressing the propensity to release
endotoxin as an amount of endotoxin per killed bacterium is
fulfilled.
Propensity to release endotoxin
There was no significant difference in the propensities to release
endotoxin between 2 h and 4 h.
At 4 h, cefuroxime released 4.8 2 2.0, 5.5 2 1.5, and
1.8 2 0.2  103 EU/killed bacterium at the concentration
levels of 2  MIC, 10  MIC, and 50  MIC, respectively.
Corresponding values for tobramycin and the combination of
tobramycin and cefuroxime were 4.3 2 1.5, 1.3 2 0.5, and
0.80 2 0.11  103 EU/killed bacterium and 2.3 2 0.1,
0.80 2 0.13, and 0.51 2 0.02  103 EU/killed bacterium,
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respectively (Figure 1). There was a significant difference
between the antibiotics investigated, with the highest pro-
pensity to release endotoxin for cefuroxime, lower for tob-
ramycin and the lowest for the combination of the two drugs
(P  0.001). With increasing doses, there was a significant
reduction (P  0.001) in endotoxin release per killed bacterium
at 10  MIC and 50  MIC for tobramycin and for the com-
bination of tobramycin and cefuroxime and at 50  MIC for
cefuroxime alone.
Similar tendencies were found between the different anti-
biotics and concentrations when comparisons were made in
terms of endotoxin release without taking the number of killed
bacteria into consideration (Table I). However, because of
increased coefficients of variation in data on endotoxin release
in comparison with those on endotoxin release per killed bac-
terium (Table 3), these comparisons lead to lower levels of
significance.
When the bacterial killing rate was correlated to the pro-
pensity to release endotoxin in bacteria exposed to tobramycin
Figure 1 Endotoxin release per killed bacterium 4 h after exposure
to antibiotics at 2  MIC, 10  MIC, and 50  MIC.
Table 3 Coefficients of variation of the increase in endotoxin
concentration and of the release of endotoxin per killed
bacterium
Increase in Release of
endotoxin endotoxin per
Antibiotic concentrationa killed bacteriuma
treatment (%) (%)
Cefuroxime 2  MIC 100 49
10  MIC 124 56
50  MIC 114 42
Tobramycin 2  MIC 134 56
10  MIC 104 51
50  MIC 124 30
Tobramycin + 2  MIC 24 11
cefuroxime 10  MIC 44 31
50  MIC 67 35
a mean of the coefficients of variation obtained at 2 h and 4 h.
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or the combination of tobramycin and cefuroxime, a significant
negative correlation was found (P  0.01) (Figure 2).
Effect of tobramycin on free endotoxin concentrations
In order to investigate whether the low endotoxin release by
tobramycin was caused by an unspecific binding, tobramycin
at varying concentrations was added to broth spiked with endo-
toxin at two concentration levels. There were no significant
changes in comparison with the control at any of the tob-
ramycin concentrations of 10, 50, and 100  MIC at any time
at either of the two endotoxin concentration levels chosen
(Figure 3).
Effect of delayed tobramycin exposure on cefuroxime-induced
endotoxin release
In the initial experiments, the highest reduction in cefuroxime-
induced endotoxin release was seen at 10  MIC (Figure 1).
Therefore, this concentration level of cefuroxime was chosen
in the further experiments in which administration of tob-
ramycin at the concentrations of 10, 50, and 100  MIC was
delayed 2 h. There were no signs of an immediate binding to
endotoxin since the endotoxin concentration was 977 2 130
EU/mL before and 990 2 85 EU/mL immediately after the
administration of tobramycin. Furthermore, with this design,
there was no significant reduction in the cefuroxime-induced
Figure 2 Relationship between endotoxin release and bacterial kill-
ing rate for tobramycin and tobramycin + cefuroxime at 2  MIC,
10  MIC, and 50  MIC, respectively.
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Figure 3 Changes in endotoxin concentration after addition of 10,
50, and 100  MIC (2.5, 12.5, and 25 mg/L) of tobramycin to broth
spiked with endotoxin at two different endotoxin levels. The shaded
area represents the 95% confidence interval based on the triplicate
measurements in the control allocated to the mean endotoxin con-
centration at time zero.
endotoxin release at any of the tobramycin concentration levels
after 4 h and there was no dose-dependency (Figure 4).
Although a slight reduction cannot be excluded, the effect on
cefuroxime-induced endotoxin release at this point of time
is small in comparison with that caused by the simultaneous
administration of cefuroxime and tobramycin.
DISCUSSION
The high degree of linearity of the regression lines (Table 2)
passing through the origin of the coordinates demonstrates that
the release of endotoxin was proportional to the reduction in
CFU, approximately depicting the number of killed bacteria,
for each antibiotic at each concentration level. Consequently,
expressing the endotoxin-liberating potential as release of endo-
toxin per killed bacterium seems to be justified.
In most in-vitro studies, endotoxin release after exposure
to bactericidal antibiotics has been measured as an endotoxin
concentration after a varying exposure time [6,7,12,14,15,17].
Since the bacterial killing rate, expressed as the time for a 2 log10
CFU reduction, in most cases is constant for each antibiotic at
each concentration level, the amount of endotoxin released will
vary with inoculum size. The methodological range in the
inoculum size is often around 20.5 log10, corresponding to a
10-fold difference in endotoxin release if the highest inoculum
is compared with the lowest one. This leads to problems when
the propensity to release endotoxin is compared with par-
ameters that are not dependent on inoculum size, such as bac-
terial killing rate, regardless whether this is expressed as the time
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Figure 4 Reduction in 4 h cefuroxime-induced endotoxin release
after addition of tobramycin at 10, 50, and 100  MIC at 2 h,
expressed as percentage of that caused by cefuroxime at 10  MIC
alone. For comparison, the result of the simultaneous exposure of
tobramycin and cefuroxime at 10  MIC, obtained from the data also
shown in Figure 1, has been included.
for a 2 log10 CFU reduction or as a reduction in the bacterial
log10 titer, as was done in a recent review [20]. Furthermore,
since the endotoxin released per killed bacterium is not depen-
dent on variation of the initial inoculum size, the inter-exper-
imental variation is considerably reduced, as seen from the
coefficients of variation, shown in Table 3. This increases the
power of the study design and the possibility to detect sta-
tistically significant differences with fewer experiments and at
lower costs.
Another advantage with the concept of ‘endotoxin release
per killed bacterium’ over the parameter of ‘increase in endo-
toxin concentration’ may be that some antibiotics with a rapid
bacterial killing look more favorable in comparison with those
having a very slow killing rate in experiments running over a
short period of time.
Cephalosporins, such as cefuroxime, cefotaxime, and cef-
tazidime, which are often recommended with or without
addition of an aminoglycoside for the treatment of severe sepsis
and septic shock, have all been shown to release substantial
amounts of endotoxin [12,15,16]. This is caused by their bind-
ing to PBP 3 which induces formation of long filaments and
endotoxin production from an increased bio-mass. In contrast,
antibiotics such as imipenem, which binds to PBP 2, results in
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conversion to spheroplasts and loss of viability with only limited
release of endotoxin [8,27].
In agreement with the results of others [12,28], the present
study has shown a substantial release of endotoxin, both expre-
ssed as increase in endotoxin concentration and as liberated
amount of endotoxin per killed bacterium, when E. coli was
exposed to cefuroxime (Table 1, Figure 1). However, at the
highest dose of cefuroxime, there was a substantial reduction
of 69% in the endotoxin release per killed bacterium. It seems
therefore reasonable to assume that cefuroxime at very high
doses may bind to PBP 1, in a similar way as has been shown
for ceftazidime, resulting in bacterial lysis without a prior for-
mation of long filaments [27]. However, the clinical relevance
of this finding is uncertain, since concentrations in the mag-
nitude of 50  MIC are only obtained for the more sensitive
strains and for a short period of time with cefuroxime in ordi-
nary dosages.
When tobramycin was added to cefuroxime, there was a
significant reduction in endotoxin release per killed bacterium
of 53, 86, and 71% at 2  MIC, 10  MIC, and 50  MIC,
respectively, compared with that caused by cefuroxime alone.
A tendency towards a similar effect was seen in the studies by
Dofferhoff et al. [12,28]. In the present study, also the com-
bination caused a corresponding reduction in endotoxin-lib-
erating capacity of 47, 37, and 36%, respectively, in comparison
with that of tobramycin alone. Thus, in terms of endotoxin
release, there seems to be an advantage in combining cef-
uroxime and tobramycin.
During recent years, there has been much interest in once-
daily dosing regimens of aminoglycosides, which has been
shown to reduce the nephrotoxicity of these drugs [23,24].
Since aminoglycosides exhibit a concentration-dependent bac-
tericidal effect and these regimens reach higher peak con-
centrations [29], it could be speculated that endotoxin release
may increase with a once-daily dosage. However, in this study,
there was a successive decrease in endotoxin liberation with
increasing antibiotic concentrations of tobramycin, and similar
results were found for the combination of cefuroxime and
tobramycin.
The initial hypothesis to explain this was that binding of
tobramycin to endotoxin would neutralize the biological
activity of endotoxin in a way similar to that demonstrated
for polymyxin B [20,21]. However, when tobramycin in the
concentrations used in the present investigation or higher was
added to BHI medium spiked with endotoxin, no substantial
reduction in endotoxin activity could be demonstrated (Figure
3). In part, this is in agreement with previous studies, since in
the study by Artenstein and Cross the neutralizing capacity of
tobramycin was small in comparison with that of polymyxin B
[30], and in the study by Foca et al. neutralization was only
around 10% [31]. Thus, in our experiments, neutralization can
be excluded as the principal explanation of the reduction in
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the cefuroxime-induced endotoxin release, because there was
neither an immediate reduction in endotoxin concentration
nor a reduction in cefuroxime-induced endotoxin release over
the following 2 h when tobramycin was added after 2 h of pre-
exposure to cefuroxime (Figure 4).
An alternative hypothesis may be that the mode of action of
tobramycin is responsible for the reduced release of endotoxin
at higher concentrations. The significant negative correlation
between the bacterial killing rates of tobramycin and the com-
bination of tobramycin and cefuroxime, on the one hand, and
the endotoxin release on the other, supports this hypothesis
(Figure 2). Failure of tobramycin to reduce cefuroxime-induced
endotoxin release if added after a 2-h pre-exposure to cefu-
roxime, indicates that initial mechanisms probably are the most
important. Previously, Kusser and Ishiguro have shown that
aminoglycosides are able to inhibit the synthesis of endotoxin
[32]. Thus, our results strongly support the hypothesis that such
a mechanism is quantitatively more important in comparison
with neutralization for the reduction in endotoxin release.
From this it follows that once-daily dosing regimens of
aminoglycosides, reaching concentrations in the magnitude, or
even higher than, those used in our study, may be of benefit,
not only in order to reduce toxicity and to achieve a more
rapid bacterial killing, but also in terms of endotoxin release.
However, details of the proposed mechanism need further
investigation.
Endotoxin release determined by the LAL assay has been
shown to be biologically active and to induce a macrophage
tumor necrosis factor (TNF) response in vitro [28]. In animal
models, there is strong evidence that soluble endotoxin released
from Gram-negative bacteria by antibiotics contributes to
pathogenesis and mortality in experimental sepsis [33].
However, the clinical significance of antibiotic-induced endo-
toxin release is still not known [20]. Anecdotal clinical data
from the studies by Dofferhoff et al. and Arditi et al. demonstrate
that increases in endotoxin concentration may be associated
with clinical deterioration [12,34] and the results from a pro-
spective clinical study in patients with Gram-negative urosepsis
by Prins et al. suggest that the difference in endotoxin release
between imipenem and ceftazidime may also be reflected by
differences in the systemic inflammatory response [13]. Fur-
thermore, a retrospective study by Mock et al. has demonstrated
that mortality was higher in trauma patients treated with endo-
toxin-releasing PBP 3-specific antibiotics than in those given
other antibiotics, which lends some support for a possible clini-
cal significance [35]. On the other hand, in a recent study by
Mauray et al. endotoxin concentration was significantly
decreased after 1 h and 4 h of antibiotic treatment in patients
with Gram-negative severe sepsis or septic shock, suggesting
that antibiotic-induced endotoxin release is not a clinically
relevant phenomenon [36]. However, in their noncomparative
study the total endotoxin concentration was measured, also
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including bacterial cell-bound endotoxin. As has been shown
by Arditi et al. in studies on children with Gram-negative men-
ingitis, there is a fall in total endotoxin concentration that
parallels the reduction in bacterial count while the biologically
active free endotoxin level concomitantly increases [34].
Taken together with the similarity between the responses of
human volunteers and animals to administration of endotoxin,
the resemblance of this response to the symptoms seen in sepsis
and septic shock [37], and the reduction in systemic inflam-
matory response demonstrated in the only hitherto published
prospective and controlled study by Prins et al. [13], available
data suggest that reduction in endotoxin release may be of
clinical importance.
In summary, with this calculation method it was possible to
demonstrate a significant reduction in endotoxin release per
killed bacterium, when the combination of cefuroxime plus
tobramycin was compared with tobramycin and cefuroxime
alone. Furthermore, increasing doses lead to significant
reductions in endotoxin release per killed bacterium, in spite
of higher bacterial killing rates. It is reasonable to believe that
both reduction in endotoxin liberation and increase in bacterial
killing rate are clinically beneficial. Due to this, it might be an
advantage to combine a PBP-3 binding b-lactam antibiotic,
such as cefuroxime, with an aminoglycoside, such as tobra-
mycin, in the treatment of severe sepsis or septic shock—at least
initially when the bacterial load is high.
Since reliable clinical studies to confirm these findings are
very difficult to conduct in this patient category [38,39], pre-
clinical studies are of major importance in order to achieve an
optimal design of such subsequent trials. The preclinical studies
should focus on different bacterial species, variations in anti-
bacterial concentrations mimicking human pharmacokinetics,
antimicrobial influence on the inflammatory response, and on
animal experiments.
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